New thinking on BRCA treatment

New thinking on BRCA treatment

PARP inhibitors have already "been used to treat advanced, BRCA-mutated ovarian cancer and have now shown efficacy in treating certain types of BRCA-mutated breast cancer", Dr. Richard Pazdur, who directs the FDA's Oncology Center of Excellence, explained in an agency news release. "This approval demonstrates the current paradigm of developing drugs that target the underlying genetic causes of cancer, often across cancer types".

During this time, 651 of the women died from breast cancer, and those with the BRCA mutation were equally likely to have survived at the two-, five- and 10-year mark as those without the genetic mutation. However, mutations of these genes may lead to certain cancers, including breast cancers.

Olaparib is the first PARP inhibitor approved beyond ovarian cancer.

The BRCA1 and BRCA2 genes usually produce molecules inside cells that help to fix DNA.

12, 2018 Young breast cancer patients with a BRCA gene mutation have the same chances of survival after treatment as those without the mutation, a new study finds.

The BRCA1 or BRCA2 gene mutations were dubbed the 'Angelina Jolie gene' after the actress underwent preventative surgery when she discovered she had an up to 87 percent chance of developing breast cancer.

In fact, they may have a "survival advantage" over non-carriers if diagnosed with triple-negative breast cancer, a form that is particularly hard to treat, a team wrote in the journal The Lancet Oncology.

More news: Wet weather with some winter mix possible going into the weekend
More news: Port Authority bombing suspect pleads not guilty 'at this moment'
More news: Trump paid porn star $130000 to stay silent over alleged affair

For the study, called POSH (Prospective Outcomes in Sporadic versus Hereditary), the researchers recruited female patients from 127 hospitals in the United Kingdom who were ages 18 to 40 when first diagnosed with invasive breast cancer, excluding those with a previous invasive malignancy.

"In particular, being able to give some women with triple negative breast cancer the choice to delay a risk-reducing mastectomy would allow them to take back control of a major part of their treatment and offer them more time to recover from their initial therapy".

Median progression-free survival (PFS) was 7.0 months in the olaparib arm vs 4.2 months in the IC arm (hazard ratio for disease progression or death, 0.58; 95% CI, 0.43-0.80; P .001).

Lynparza does come with side effects, which can include anemia, low white blood cell counts, nausea, fatigue, vomiting, headache, joint pain, increased susceptibility to colds and other respiratory tract infections, and other effects.

Young women with breast cancer have the same survival rates regardless of whether they have faulty BRCA genes, researchers have said.

Lynparza is sponsored by AstraZeneca Pharmaceuticals LP.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.